Document:

Processing and Packaging Agreement

 Exhibit 10.44 
 PROCESSING AND PACKAGING AGREEMENT 
 THIS AGREEMENT (the “Agreement”) dated
as of January 7, 2003, by and between GFA BRANDS, INC., an Ohio corporation, with its principal place of business at 211 Knickerbocker Road, P.O. Box 397, Cresskill, New Jersey, 07626-0397 (the “Company”), and CREATIVE FOODS
LLC, a Delaware limited liability company with its principal place of business at 710 North Pearl, Osceola, Arkansas, 72370 (“Co-Packer”). 
 WITNESSETH: 
 WHEREAS, Co-Packer operates a food manufacturing plant at Osceola, Arkansas; and

 WHEREAS, the Company wishes to engage Co-Packer for the purpose of manufacturing, processing and packaging certain food products
for the Company at such plant. 
 NOW, THEREFORE, in consideration of the premises and of the mutual promises and covenants
hereinafter set forth, the parties hereto agree as follows: 
  

	1.0	Products and Their Manufacture/Packaging. 

 1.1 The products to be manufactured, processed and packaged by Co-Packer for the Company hereunder shall be the food products listed on Exhibit A attached hereto and incorporated herein by reference, as may be amended from time to time with
the mutual agreement of the parties (collectively, the “Product”). Co-Packer shall manufacture and process the Product in accordance with certain formulas and specifications to be provided by the Company, good manufacturing processes,
specifications, information, and finished product standards, all as set forth in Exhibit B attached hereto and incorporated herein by reference. Co-Packer shall at all times comply with and conform its activities hereunder to the provisions of
Exhibit B and provide to the Company samples of each production run at no cost to the Company other than the cost of shipment of such samples. The Company may at any time amend Exhibit B by giving thirty (30) days’ prior written notice to
Co-Packer of any such amendment. Co-Packer shall package the Product in conformity with the specifications supplied by the Company, which are attached hereto as Exhibit C and incorporated herein by reference. All packaging labels for the Product
shall have been approved by the Company prior to use. 
 1.2 The Company shall give to Co-Packer a rolling six (6) month estimate of its
Product needs on the first day of the term hereof and on the first day of each mouth thereafter during the term hereof, in order to assist Co-Packer in establishing a tentative production schedule and to purchase adequate packaging supplies. The
Company shall issue orders for a specific Product through written purchase orders as set forth in Exhibit D attached hereto. In all instances, the Company’s liability for Product will be limited to the estimates provided by the Company to
Co-Packer and any written purchase orders. The Company’s liability for packaging materials ordered by Co-Packer will be for the estimated volumes for the upcoming six (6) month period, and any packaging materials ordered to meet minimum
order quantities. 

  

 1 

 
Co-Packer will advise the Company anytime a minimum packaging supply order exceeds the applicable six (6) month forecasted volume prior to ordering
supplies. All orders for Products will be shipped within seven (7) business days of the specified shipment date in each of the Company’s purchase orders. For purposes of this Agreement, business days shall mean Monday through Thursday of
each week, unless any of such days are holidays. 
 1.3 Co-Packer shall maintain and retain accurate records of production and its standard
quality control data, as well as all other records required to be kept by applicable local, state or federal law or as may be reasonably requested by the Company. Further, Co-Packer’s quality control department will prepare its standard reports
for each production run. Such records shall be available to the Company for audit verification, upon giving reasonable advance notice to Co-Packer and upon signing Co-Packer’s standard Visitor Confidentiality Agreement, during Co-Packer’s
regular business hours and shall be retained by Co-Packer for the Company’s use for at least one (1) year after completion of production. 
 1.4 During the term hereof, the Company shall purchase all of its requirements for the Product from Co-Packer. 
 1.5 The Company
hereby represents and warrants to Co-Packer, that it is the owner of, or is otherwise authorized to use, all formulas, processes, specifications, information, materials, trade secrets, trademarks, logos, and finished product standards furnished by
it to Co-Packer pursuant to this Agreement (the “Company Materials”), and that the use by either Co-Packer or the Company of any or all of the Company Materials, pursuant to the terms of this Agreement, will not infringe upon or violate,
in any manner or fashion, the rights of any third party, whether located in the United States or any other part of the world. In addition, the Company hereby agrees to indemnify, hold harmless, and defend Co-Packer from and against any and all
liabilities, damages, injuries, claims, suits, expenses (including reasonable attorneys’ fees, court costs, and out-of-pocket expenses) resulting from or arising out of Co-Packer’s use of the Company Materials in connection with this
Agreement. 
 1.6 During the term hereof, Co-Packer will maintain an OU rabbinical certification. 
  

	2.0	Term and Termination. 

 2.1 This Agreement
shall commence on the date hereof and shall continue for a period of one (1) year, subject to earlier termination pursuant to the provisions of this Section 2.0. The term shall be automatically extended thereafter for additional one
(1) year periods, unless either party shall notify the other of its intent not to renew at least one hundred eighty (180) days prior to the end of the initial or any renewed term, as the case may be. 
 2.2 Each party shall have the right to terminate, without cause, this Agreement at any time in its sole discretion by providing the other party one
hundred eighty (180) days’ prior written notice. 
 2.3 Either party may immediately terminate this Agreement if a Default, as
defined below, by the other party has occurred and is continuing by giving written notice thereof to the 

  

 2 

 
defaulting party. Except as otherwise specifically provided herein, and subject to the provisions of Section 2.4 hereof, termination of this Agreement
shall not relieve the defaulting party of any obligation accruing with respect to this Agreement prior to such termination. The term “Default” shall mean any of the following: 
 (a) Failure by a party to comply with or to perform any material provision or condition of this Agreement for ten (10) days after
receipt of written notice thereof by such party; or 
 (b) A party becomes insolvent, is unable to pay its debts as they
mature or is the subject of a petition in bankruptcy, whether voluntary or involuntary, or of any other proceeding under bankruptcy, insolvency or similar laws; or makes an assignment for the benefit of its creditors; or is named in, or its property
is subject to a suit for appointment of a receiver; or is dissolved or liquidated; or 
 (c) Any material warranty made in
this Agreement is breached, false, or misleading in any material respect. 
 Subject to Section 2.5 hereof, in the event of such
termination, the non-defaulting party shall be entitled to pursue any remedy provided at law or in equity, including injunctive relief and the right to recover any damages it may have suffered by reason of such Default; provided, further, in the
event of a termination of this Agreement by Co-Packer, Co-Packer’s damages shall include, but not be limited to, the Equipment Return Expense, as defined herein. 
 2.4 Upon termination of this Agreement, all rights, obligations, and causes of action accruing hereunder prior to such termination shall survive and the provisions of this Agreement shall continue to be controlling
for the purpose of determining the rights of the parties hereto. The waiver or repeated waiver by either party hereto of any breach of any provision of this Agreement by the other party shall not be deemed a waiver of a fixture breach. 

2.5 Notwithstanding anything to the contrary herein, neither party shall be liable to the other party for consequential, exemplary, special,
incidental, or punitive damages hereunder. 
 2.6 The provisions of Sections 2.0, 3.0, 8.0, 9.0, and 10.0 hereof shall survive any
termination of this Agreement. 
 2.7 Upon the expiration or termination hereof, the Company shall, immediately, take delivery of and pay for
all Product and raw ingredients and packaging relating to the Product which is in Co-Packer’s inventory and/or which had been ordered by Co-Packer, pursuant to the terms of section 1.2 hereof, prior to the expiration or termination hereof, as
the case may be. 
  

	3.0	Confidentiality. 

 3.1 In order for Co-Packer
to perform the services provided hereunder, each party must disclose to the other party certain information, including, but not limited to, formulas, processes, specifications, trade secrets, know-how, the Product, customer names, and business

  

 3 

 
data which the disclosing party considers to be proprietary and confidential. The receiving party shall regard as confidential and proprietary all of the
information communicated to it by the disclosing party in connection with this Agreement (which information shall at all times be the property of the disclosing party). The receiving party shall not, without the disclosing party’s prior written
consent, at any time (a) use such information for any purpose other than in connection with the performance of its obligations under this Agreement or (b) disclose any portion of such information to third parties. The receiving
party shall promptly upon the expiration or earlier termination of this Agreement return to the disclosing party, without retaining copies thereof, all such information which is in written or tangible form (including, all copies, summaries and notes
of the contents thereof), regardless of the party causing the same to be in such form, and destroy all written materials prepared by the receiving party which incorporate or include any such information. The receiving party shall disseminate such
information to its employees only on a “need-to-know” basis. The receiving party shall cause each of its employees who has access to such information to comply with the terms and provisions of this Section 3.1 in the same manner as
the receiving party is bound hereby, with the receiving party remaining responsible for the actions and disclosures of any such employees. In addition, except as otherwise provided herein, the receiving party shall not, without the disclosing
party’s prior written consent, disclose to third parties any information developed for the disclosing party by the receiving party or the nature of and discussions regarding this Agreement. The receiving party agrees that any breach of this
Section 3.1 by the receiving party or its employees shall cause irreparable injury to the disclosing party, that the disclosing party shall be entitled to specific performance and injunctive or other equitable relief as a remedy for any such
breach, and that the receiving party agrees to waive any requirement for the securing or posting of any bond in connection with such remedy. 
 Notwithstanding the foregoing, the receiving party’s obligations pursuant to this Section 3.1 shall not apply to (a) information that, at the time of disclosure, is, or after disclosure becomes part of, the public domain
other than as a consequence of the receiving party’s breach of its obligations hereunder, (b) information that was known or otherwise available to the receiving party (as evidenced by the receiving party’s written records) prior to
the disclosure by the disclosing party, (c) information disclosed by a third party to the receiving party after the disclosure by the disclosing party, if such third party’s disclosure neither violates any obligation of the third party to
the disclosing party nor is a consequence of the receiving party’s breach of its obligations hereunder, or (d) information that the Company authorized in writing for release. 
 This Agreement is also subject to the confidentiality provisions contained in that certain Confidentiality Agreement between the parties, dated as of
June 18, 2002. In the event of any conflict between the terms of this section and the foregoing Confidentiality Agreement, then, in any such event, the terms of this section 3.0 shall govern 
  

	4.0	Right of Inspection. 

 4.1 The Company shall
have the right to inspect Co-Packer’s plant and to review Co-Packer’s records pertaining to the Product and services hereunder to the extent necessary to protect its rights under this Agreement and Co-Packer agrees that representatives of
the Company shall have access, during Co-Packer’s normal business hours and upon signing 

  

 4 

 
Co-Packer’s standard Visitor’s Confidentiality Agreement, to Co-Packer’s premises for the purpose of inspecting Product prior to delivery
thereof to the Company or its customers. If such inspection and/or review by the Company reveals that the processes, procedures, practices or the like used by Co-Packer with respect to its services hereunder fail to conform to Exhibits B and C,
Co-Packer shall immediately take appropriate corrective actions (which may include suspension of Co-Packer’s services hereunder), at the Company’s complete direction, until Co-Packer can demonstrate to the Company’s satisfaction that
its non-conforming activities have been corrected. 
 4.2 The Company shall be under no obligation to undertake such inspection and, whether
or not the Company inspects the Product or Co-Packer’s facilities, it shall not affect or release Co-Packer from any of the obligations provided herein and none of the obligations of Co- Packer with respect to the Product shall be affected or
released by the Company’s (or its customers’) acceptance of delivery of Product or by any inspection thereof or by payment therefor. 
 4.3 Co-Packer shall notify the Company immediately of any audits which indicate the presence of listeria monocytogenes, salmonella, or E. Coli in the Product. Co-Packer shall also inform the Company immediately of any inquiry, investigation
or inspection by any federal, state or local governmental agency from which may arise (a) a request by such governmental agency for a Company product sample or (b) significant adverse findings such as, by the way of example and not by way
of limitation, exposed Product near chemicals, or rodent or insect infestation. 
 4.4 Upon signing Co-Packer’s standard Visitor’s
Confidentiality Agreement, the Company may be represented on site by a representative during each production run of Product. The Company’s representative shall have the right to audit Co-Packer’s operation for compliance with all
provisions of this Agreement. The representative shall be and remain the employee and authorized agent of the Company, and Co-Packer shall provide the representative with suitable working space at the production facility of Co-Packer. The
Company’s representative shall have unrestricted access, at all times, to all portions of the storage, production, and other facilities of Co-Packer which are involved in, committed to, or have an effect on the production of Product hereunder.
The parties agree that in case of an emergency affecting the quality of the Product, the Company’s representative shall have free access, upon notice to Co-Packer, to those areas of Co-Packer’s premises concerned with or affecting the
manufacturing, processing or packaging of the Product to deal with such emergency. 
 4.5 Notwithstanding anything to the contrary contained
herein, under no circumstances shall the Company’s representatives, agents or contractors have access to Co-Packer’s plant and facilities, unless each such representative, agent, or contractor signs Co-Packer’s standard Visitor’s
Confidentiality Agreement. 
  

	5.0	Licenses. 

 This Agreement shall not be
construed to be or to contain an express or implied license by the Company to Co-Packer under any patents, patent applications, trademarks, trade names, label design, color combination, insignia or other intellectual properties owned by the Company

  

 5 

 
or its customers. Co-Packer represents, warrants, and agrees that it shall not use packaging supplies that may be provided by the Company except for packing
the Product, and that such packaging supplies shall not be sold, assigned, given, transferred to third parties, or otherwise disposed of without the Company’s prior written consent. Notwithstanding anything to the contrary herein, Co-Packer
shall be entitled, at all times, during and after the term hereof, to create, develop, produce, manufacture, distribute, and sell, for or to, as the case may be, competitors of the Company products, which are similar to the Product. 
  

	6.0	Price and Payment. 

 6.1 The Company shall
pay Co-Packer the prices stated in Exhibit E, attached hereto and incorporated herein by reference, and as may be amended from time to time with the mutual agreement of the parties, for the services being performed pursuant to this Agreement. Such
payments shall be made to Co-Packer at the address set forth in the preamble hereof Notwithstanding anything to the contrary herein, to the extent the cost of any ingredients or packaging changes, which is procured by Co-Packer through a vendor
specified by the Company, each such change and cost thereof will be, immediately, passed-on by Co-Packer to the Company. 
 6.2 Delivery of
the Product shall be F.O.B. Co-Packer’s plant in Osceola, Arkansas. Co-Packer shall invoice the Company for each shipment, indicating the Product description, Product number and quantities shipped. The invoices should be sent to the Accounts
Payable Department of the Company and include a copy of the bill of lading as appropriate. The Company shall make payment within thirty (30) days from the date of Co-Packer’s invoice; provided, however, in the event that any invoice is
paid by the Company within ten (10) days of the date of such invoice, the Company shall be entitled to a one percent (1%) discount, in connection with each such invoice paid within ten (10) days of the date thereof. In the event that
the parties ship products in conjunction with each other, the cost of each such shipment shall be allocated on a pro-rata basis between the parties based upon the invoices furnished by the trucking line. 
  

	7.0	Storage and Shipment. 

 7.1 Co-Packer agrees
to load and ship the Product, F.O.B. Dock, Co-Packer’s plant in Osceola, Arkansas, on such carriers, to such destinations, and in such quantities as may be designated by the Company. The bill of lading should include Product description,
Product number, and release order number. 
 7.2 All Product supplied by Co-Packer to the Company hereunder shall be free of any and all
liens, claims, and encumbrances of any kind, other than in favor of Co-Packer, until payment for the Product is received by Co-Packer. 
 7.3
From time to time, upon each receipt of a written request from the Company, Co-Packer will store the Product in such amounts, for such periods of time and for such storage charges as are mutually agreed-to by the parties, which storage charges shall
commence accruing from the thirtieth (30th) day of storage of any Product for the Company; provided, however, after 

  

 6 

 
any product has been stored for thirty (30) days, Co-Packer shall invoice the Company for the purchase price of any such Product, and the Company shall
pay such purchase price in accordance with the terms of section 6 hereof. Notwithstanding anything to the contrary herein, to the extent that the Company does not take delivery of any Product which has been stored for in excess of six
(6) months, Co-Packer shall have no responsibility whatsoever as to whether such Product is fit for human consumption, and the Company shall indemnify, hold harmless, and defend Co-Packer from any and all liabilities arising from the use of any
such Product. The foregoing is subject to Co-Packer having sufficient warehouse space to store the Product. 
  

	8.0	Warranty and Pure Food Guaranty. 

 Co-Packer
represents and warrants that: 
 (a) All Product delivered pursuant to this Agreement will be in strict conformity with the
specifications set forth in Exhibits B and C and will be merchantable food product suitable for human consumption; 
 (b) All
Product shipped or delivered pursuant hereto, as of the date of such shipment or delivery FOB Co-Packer’s plant, will not be, on such date, (a) adulterated or misbranded within the meaning of the Federal Food, Drug and Cosmetic Act;
(b) an article which may not, under the provisions of sections 404 or 505 of said federal Act, be introduced into interstate commerce; and (c) adulterated or misbranded within the meaning of laws or ordinances of the state or city to which
such Product is shipped by Co-Packer, the adulteration and misbranding provisions of which are substantially the same as those found in said federal Act; and 
 (c) That all Product delivered pursuant to this Agreement will be in compliance with the Federal Consumer Product Safety Act, 15 U.S.C.
Section 2051, et seq. and its implementing regulations at 16 C.F.R. Part 1500. 
 Notwithstanding anything to the contrary
herein, the Company shall indemnify, hold harmless, and defend Co-Packer from any liability under the above laws for any type of misbranding which arises from the use of the Company’s labels or labeling prepared based upon the Company’s
instructions, or for any liability under such laws for misbranding where the Company insists upon the use of any label after Co-Packer has questioned in writing the use of such label. 
  

	9.0	Unacceptable Product. 

 For purposes of this
Section 9.0, “Unacceptable Product” shall mean any one of the following: 
 (a) At time of delivery, the
Product fails to meet the specifications set forth in Exhibit B; 
 (b) The packaging and/or the Product do not meet the
Company’s standards as set forth in Exhibits B and C; 
  

 7 

 (c) The Product is adulterated or misbranded within the meaning of the Federal Food, Drug
and Cosmetic Act or fails to meet the requirements of Section 8(b) hereof; and/or 
 (d) The Product fails to meet the
warranties of this Agreement with respect thereto. 
 In the event that the finished Product or any part thereof shall, for any reason, be
Unacceptable Product, the Company (or its customers) may refuse to accept delivery thereof and Co-Packer shall not sell or otherwise dispose of the same under the Company’s (or its customers’) name(s) or label(s) without the Company’s
prior written consent. If such Unacceptable Product shall have been delivered to the Company or its customers, the Company shall dispose of such Unacceptable Product in a manner as the circumstances may reasonably dictate and Co-Packer shall
reimburse the Company for any amount by which the sale or disposal price realized by the Company shall be less than the Company’s cost of the Product plus reasonable expenses for such sale or disposition. In the event Unacceptable Product is
determined by the Company to be spoiled through no fault of the Company, or otherwise suitable for disposal only as waste, Co-Packer shall replace all such Unacceptable Product at no cost to the Company and, in addition, reimburse the Company for
all reasonable costs of handling and/or disposal of such Product. Subject to Section 8.0 hereof, and notwithstanding any other provision of this Section 9.0, Co-Packer shall not be required to reimburse the Company or any other party for
Unacceptable Products or any other costs whatsoever associated or incurred in connection therewith, if the unacceptability resulted from the acts, omissions, or willful misconduct of the Company (or its customers), or any other third party, which is
unrelated to and not affiliated with Co-Packer. For the avoidance of doubt, notwithstanding anything to the contrary herein, in the event any Product does not meet or comply with the specifications set forth herein, or is otherwise Unacceptable
Product, as a result of the acts, omissions, negligence, or misconduct of any vendor that the Company designated as a vendor that Co-Packer should use in connection with the procurement of any ingredients to be used in connection with manufacturing
the Product, then, in any such event, Co-Packer shall not have any liability whatsoever to the Company or its customers for any such Unacceptable Product, and the Company shall indemnify, hold harmless, and defend Co-Packer from any and all
liabilities, damages, losses, injuries, claims, suits, and expenses (including attorneys’ fees, court costs, and out-of-pocket expenses) associated with, or arising in connection with, directly or indirectly, the manufacture, shipment,
purchase, sale, use, and/or consumption of any such Unacceptable Product. 
  

	10.0	Indemnification and Insurance. 

 10.1
Co-Packer shall indemnify, hold harmless and defend the Company, its employees and agents, from and against any and all liabilities, damages, injuries, claims, suits, expenses (including reasonable attorneys’ fees, court costs and out-of-pocket
expenses) (a) brought by a lawful governmental authority against or concerning the Product or any portion thereof; or (b) that may in any way arise from breach of warranty, express or implied, or any tort 

  

 8 

 
actions or claims, as to the quality of the Product, or any portion thereof, its merchantability, its fitness for the purpose for which it was sold, or the
failure of the Product to maintain its quality standard for the duration of the Product’s shelf life, except for such liabilities, damages, injuries, claims, suits, expenses (including attorneys’ fees, court costs, and out-of-pocket
expenses) caused by the acts, omissions, or willful misconduct of the Company, the Company’s employees, the Company’s customers, or third parties which are unrelated to and not affiliated with Co-Packer. 
 10.2 Co-Packer shall also indemnify, hold harmless and defend the Company, its employees and agents, against any losses or damages to the Product and any
the Company property, if any, located in Co-Packer’s plant during the term of this Agreement. 
 10.3 The Company shall, within ten
(10) days after receipt of notice of the initiation of any legal proceedings against the Company, relating to the Product, notify Co-Packer thereof and, if required hereunder, Co-Packer shall indemnify, hold harmless and defend the Company in
such proceedings. 
 10.4 Co-Packer shall maintain, throughout the term of this Agreement, at its expense, with a carrier or carriers
reasonably satisfactory to the Company: 
 (a) Commercial/comprehensive general liability insurance (including product
liability and vendor’s liability insurance) in a minimum amount of Two Million Dollars ($2,000,000) combined single limit, for bodily injury (including death resulting therefrom) and property damage, and endorsed to provide contractual
liability insurance in the amount specified above, specifically covering Co-Packer’s obligations to indemnify the Company pursuant to this Section 10; 
 (b) Comprehensive automobile liability coverage for all owned, non-owned and hired vehicles with bodily injury limits of not less than One
Million Dollars ($1,000,000) per accident; and 
 (c) Statutory workers’ compensation coverage meeting all state and
local requirements, including coverage for employers’ liability with limits of not less than Five Hundred Thousand Dollars ($500,000), including a waiver of subrogation in favor of the Company. 
 A certificate of insurance evidencing such coverages shall be delivered to the Company upon the commencement of the term hereof and annually thereafter
during any renewal terms. The certificate shall specify that the Company shall be given at least thirty (30) days prior written notice by the insurer(s) in the event of any material modification, cancellation or termination of the coverage. The
insurance certificates required under subsections (a) and (b) above shall designate the Company as an additional insured. The insurance must be primary coverage without right of contribution from any other Company insurance. Insurance
maintained by the Company is for the exclusive benefit of the Company and will not inure to the benefit of Co-Packer. 
  

 9 

	11.0	Independent Contractor. 

 Nothing contained
herein shall be deemed or construed to create any partnership or joint venture between the Company and Co-Packer. The operation of any equipment or machinery or devices used by Co-Packer and the employment of labor to manufacture, process, package,
pack, code date, stencil, store, assemble, load and deliver the Product shall be the sole responsibility of Co-Packer. All activities by Co-Packer under the terms of this Agreement shall be carried out by Co-Packer as an independent contractor and
not as an agent for or employee of the Company. Under no circumstances shall any employee of Co-Packer be deemed or construed to be an employee of the Company. The Company shall not be liable for any injuries or damages incurred by Co-Packer or its
agents or employees as a result of its activities in the performance of this Agreement. 
  

	12.0	Special Representations and Warranties. 

 12.1 Co-Packer represents and warrants that it is capable of performing under the terms of this Agreement and that it has or will obtain all necessary equipment and labor to perform the services under this Agreement. In addition, Co-Packer
warrants that it has or will duly obtain any and all licenses, permits, and authority necessary or required to perform its obligations under this Agreement; that it is in good standing, to the extent necessary to perform its obligations hereunder,
with all governmental bodies or agencies, whether of state, federal or local governments, and that it will take such steps and perform such acts as may be necessary to retain such good standing; that it has full right and authority to enter into
this Agreement and to perform all of its obligations hereunder; and that it has performed all acts and taken all steps necessary to authorize the execution of this Agreement. 
 Notwithstanding anything to the contrary herein, the Company shall be responsible for delivering, in good working order, and furnishing, during the
entire term hereof, at its expense, to Co-Packer an ADCO Model 12 WA-70 stainless steel Wrap-Around Sleever (the “Equipment”), which is necessary for Co-Packer to perform its obligations hereunder. During the term hereof; Co-Packer shall
maintain, repair, and insure such Equipment, in the amount of U.S. Dollars One Hundred Thousand ($100,000). Such insurance shall name the Company and Co-Packer as coinsureds. Further, to the extent any maintenance or repairs of the Equipment are
covered by a warranty thereon, the Company shall make available, at its expense, the full benefits of any such warranty to Co-Packer. Upon the termination or expiration of this Agreement, as the case may be, Co-Packer shall return the foregoing
equipment to the Company, at the Company’s expense, which expense shall also include the cost of dismantling the Equipment (collectively, the “Equipment Return Expense”), in the same condition as received, reasonable wear and tear
excepted. 
 12.2 The Company hereby represents and warrants that it has the full right and authority to enter into this Agreement and to
perform all of its obligations hereunder; and that it has performed all acts and taken all steps necessary to authorize the execution of this Agreement. 
  

 10 

	13.0	Force Majeure. 

 If either party hereto is
prevented from complying, either totally or in part, with any of the terms or provisions of this Agreement by reason of fire, shortages of food ingredients, packaging or transportation, flood, storm, strike, lockout or other labor trouble, riot,
war, rebellion, or other acts of God, then upon written notice to the other party, the affected provisions and/or other requirements of this Agreement shall be suspended during the period of such disability. The disabled party shall make all
reasonable efforts to remove such disability within thirty (30) days of giving notice of such disability. If the disability continues for more than ten (10) days after the cessation of the reason for such disability, the non-disabled party
shall have the right to terminate this Agreement, and neither party shall thereafter have any further rights or obligations hereunder, except as set forth in Section 2.0. During said period, the non-disabled party may seek to have its needs,
which would otherwise be met hereunder, met by others without liability to the disabled party hereunder. In no event shall an event of force rnajeure constitute a basis for the Company to delay to cease compliance with its payment obligations
hereunder. 
  

	14.0	Miscellaneous. 

 14.1 Co-Packer acknowledges
that the services to be rendered by it to the Company are unique and personal. Accordingly, Co-Packer may not assign any of its rights or delegate any of its obligations under this Agreement to another party, including, for example, use of a
co-packer, without the prior written consent of the Company, which consent shall not be unreasonably withheld, delayed, denied, or conditioned. This Agreement shall inure to the benefit of the parties hereto and their respective successors and
permitted assigns. 
 14.2 All notices, reports, and receipts shall be in writing and shall be deemed duly given on (a) the date of
personal or courier delivery; (b) the date of transmission by telecopy or other electronic transmission service, provided a confirmation copy is also sent no later than the next business day by certified mail, postage pre-paid, return receipt
requested; or (c) three (3) business days after the date of deposit in the United States Mail, by certified mail, postage prepaid, return receipt requested, addressed as follows: 
  

					
	If to Co-Packer:	  	Creative Foods LLC
		  	 P.O. Box 368
 710 North Pearl
 Osceola, Arkansas 72370

		  	Attention:    	  	     Mr. W. Michael Anderson
     Executive Vice-President

		  	 Telecopier No. 870-563-2223
 Telephone
No. 800-643-0006

		
	If to the Company:	  	 GFA Brands, Inc.
 211 Knickerbocker
Road
 P.O. Box 397
 Cresskill, New Jersey
07626-0397

  

 11 

					
		  	Attention:    	  	     Mr. Robert M. Harris
     President

		  	 Telecopier No. 201-568-6374
 Telephone
No. 201-568-9300

 Either party may change its mailing address by written notice to the other party accordance with
this Section 14.2. 
 14.3 This Agreement constitutes the entire Agreement and understanding between the parties regarding the subject
matter hereof, and supersedes and merges all prior discussions and agreements between them relating thereto. No waiver, modification or amendment to this Agreement shall be valid unless in writing, signed by the parties hereto. 
 14.4 The rights and obligations of the parties to this Agreement shall be governed by, interpreted, performed, and enforced in accordance with the
substantive laws of the State of Arkansas, without reference to principles of conflict of laws; provided, however, initiation and conduct of any arbitration proceedings hereunder shall be governed in all respects exclusively by the Commercial
Arbitration Rules of the American Arbitration Association, and the Federal Arbitration Act, Title IX, United States Code. 
 14.5 Whenever
possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under applicable law, such provision shall be
ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. 
 14.6 This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute the entire Agreement. 
 14.7 The failure or delay of either party to insist upon the other party’s strict performance of the provisions in this Agreement or to exercise in
any respect any right, power, or remedy provided for under this Agreement shall not operate as a waiver or relinquishment thereof; nor shall any single or partial exercise of any right, power or remedy preclude any other or further exercise thereof;
or the exercise of any other right, power or remedy; provided, however, that the obligations and duties of either party with respect to the performance of any term or condition in this Agreement shall continue in full force and effect. 

14.8 The headings in this Agreement are for convenience only, and are not to be construed as part of the Agreement and shall not in any way effect the
interpretation of this Agreement. 
 14.9 It is expressly agreed between the parties hereto that any controversy or claim between them,
arising out of or in connection with, or relating to the enforcement, nonenforcement, interpretation, performance, or breach of, any provision of this Agreement shall be settled exclusively by arbitration in the City of Memphis, State of Tennessee,
in accordance with the Commercial Arbitration Rules of the American Arbitration Association in effect at the time 

  

 12 

 
any arbitration proceeding is commenced, which Rules are hereby incorporated by reference and made a part of this Agreement. The arbitration shall be
conducted before and determined by a panel of three arbitrators, who shall be appointed by the American Arbitration Association in accordance with said Commercial Arbitration Rules. The arbitration award issued by the arbitrators shall be final and
binding on both parties and judgment upon such arbitration award may be entered in any court having jurisdiction. 
 Either party may,
without inconsistency with the foregoing agreement to arbitrate, seek from any court of competent jurisdiction any interim or provisional relief or remedy (including injunctive relief) which may be necessary to protect its property or rights pending
the establishment of the arbitration panel or its determination of the merits of the controversy. 
 IN WITNESS WIIEREOF, the parties have
duly executed this Agreement as of the date first above written by their respective authorized representatives. 
  

									
	GFA BRANDS, INC.	 		 	 CREATIVE FOODS LLC
   By:
Osceola Foods, Inc., its sole manager

					
	By:	 	/s/ Peter L. Dray	 		 	By:	 	/s/ W.M. Anderson
	Name:	 	Peter L. Dray	 		 	Name:	 	W.M. Anderson
	Title:	 	Vice President	 		 	Title:	 	Executive Vice President

  

 13 

 EXHIBIT A 
 Food Products 
 12/8oz. Smart Balance Plus 
 12/8oz. Natucol Buttery Spread 
  

 14 

 EXHIBIT B 
 Food Product Specifications 
 See attached 
  

 15 

 Certain portions hereof denoted with “[***]” have been omitted pursuant to a request
for confidential treatment. An unredacted copy hereof has been filed separately with the United States Securities and Exchange Commission pursuant to a request for confidential treatment. 
 QC RANGES FOR EARTH BALANCE NATUCOLTM SPREAD 
  

					
	 % Moisture, product:
	  	Target ***%; Range ***% - ***%.
		
	 % Salt, product
	  	Target ***%; Range ***-*** %.
		
	 % Moisture, milk
	  	Target ***%; Range ***-***%
		
	 % Salt, milk
	  	Target ***%; range. ***-***% Salt.
		
	 pH:
	  	Range ** in Aqueous Phase
			
	 Palm Blend P
	  		  	
			
		  	PV upon receipt	  	<*** meq/kg
			
		  	IV	  	****
			
		  	FFA	  	£***%
			
		  	moisture	  	£***%
			
		  	appearance	  	clear when melted

 Finished Product Microbiological Tests 
  

			
	 Coliform/gram
	  	*** max
		
	 Yeast/gram
	  	*** max
		
	 Mold/gram
	  	*** max

 Cup Weight:             Target, ***g; Range ***g to
***g (***-*** lb) 
  

			
	 GFA Brands, Inc.
 Revised August 22,
2002
	 	Prepared for Creative Foods, Osceola AR

  

 16 

 Certain portions hereof denoted with “[***]” have been omitted pursuant to a request
for confidential treatment. An unredacted copy hereof has been filed separately with the United States Securities and Exchange Commission pursuant to a request for confidential treatment. 
 QC RANGES FOR SMART-BALANCETM
PLUS SOFT SPREAD 
  

			
	 % Moisture, product.
	  	Target ***%; Range ***% - ***%.
		
	 % Salt, product
	  	Target ***%; Range: ***% - ***%
		
	 % Moisture, milk
	  	Target ***%; Range *** - ***%
		
	 % Salt, milk
	  	Target ***%; Range ***-***%.
		
	 pH
	  	Range *** in Aqueous Phase
		
	 Palm Blend P:
	  	

  

			
	PV upon receipt	 	*** meq/kg
		
	IV	 	***
		
	FFA	 	£***%
		
	Moisture	 	£***%
		
	appearance	 	clear when melted

 Finished Product Microbiological Tests 
  

			
	 Coliform/gram
	  	*** max
		
	 Yeast/gram
	  	*** max
		
	 Mold/gram
	  	*** max

 Cup Weight
                    Target, *** g; Range *** g to *** g (**** – **** lb) 
  

			
	 GFA Brands, Inc.
 Revised August 22,
2002
	 	Prepared for Creative Foods, Osceola AR

  

 17 

 Certain portions hereof denoted with “[***]” have been omitted pursuant to a request
for confidential treatment. An unredacted copy hereof has been filed separately with the United States Securities and Exchange Commission pursuant to a request for confidential treatment.  
  

			
	 

	 	PROPRIETARY & CONFIDENTIAL

  

			
	Product Name:	  	Palm Blend P
	Product Number:	  	4378
	Formula:	  	*****
	Effective:	  	10/11/02

 Description: A proprietary blend of palm, soybean and canola oils suitable for manufacture of tub
type spreads. 
 Ingredient Line: Palm, soybean and canola oils 
 Analytical 
  

			
	 Color, Lovibond
	  	 *** – *** MAX

	 Free Fatty Acids, %
	  	 *** MAX

	 Peroxide Value, MEQ/KG as delivered
	  	 *** MAX

	 Moisture, %
	  	 *** MAX

	 Iodine Value
	  	 *** – ***

	 Trans Acids, %
	  	 *** MAX

 Packaging 
 Tank Truck 
  

 18 

 EXHIBIT C 
 Packaging Specifications 
 See attached 
  

 19 

 

 
  

 20 

 

 
  

 21 

 Entire page omitted pursuant to a request for confidential treatment and filed separately with the United States
Securities and Exchange Commission. 
  

 22 

 Entire page omitted pursuant to a request for confidential treatment and filed separately with the United States
Securities and Exchange Commission. 
  

 23 

 Entire page omitted pursuant to a request for confidential treatment and filed separately with the United States
Securities and Exchange Commission. 
  

 24 

 EXHIBIT D 
 Form of Purchase Order 
 See Attached 
  

 25 

 

 
 * ATTN: REBEL NICHOLS X-523 ** 
 GFA FAX ORDER 10/10/02 
 ORDER # 34618 
 PLANT #12 CREATIVE FOODS LLC 
 G1009 
 SHIP
TO: 
 SCHREIBER FOODS INC 
 PO NUMBER: 
 PRODUCTION ORDER 
 MISSOURI DISTRIBUTION CTR 
 SHIP DATE: 
 10/30/02 
 #1 CIVIL WAR ROAD 
 ARRIVAL DATE: 
 10/31/02 
 CARTHAGE MO 64836 
 SHIP VIA: 
 TRUCK 
 SHIP INSTRUCTIONS: 
 CFA 417-358-8055 
 BEN QUADE. 
 DO NOT MIX CODES ON PLT. 
 ITEM # 
 UPC

 QTY 
 PACK/SIZE 
 DESCRIPTION 
 10440 
 01910 
 1200 
 12/8 OZ

 EARTH BAL NATUCOL SPREAD 1.0840 
 10439 
 01930 
 6000 
 12/8 OZ

 SMART BALANCE PLUS 1.01500 
 TOTAL LIKE ITEMS: 
 2 
 TOTAL CASES: 
 7,200 
 TOTAL WT: 
 53,280.00 LBS 
 ** TOTAL PAGE.001 ** 
  

 26 

 Certain portions hereof denoted with “[***]” have been omitted pursuant to a request
for confidential treatment. An unredacted copy hereof has been filed separately with the United States Securities and Exchange Commission pursuant to a request for confidential treatment. 
 EXHIBIT E 
 Food Product Prices

 Processing Toll of $****/lb over Packaging & Ingredients 
 Packaging ***% Shrink 
 Ingredients ***% Shrink until statistical data base established

  

 27License Agreement

 Exhibit 10.45 
 LICENSE AGREEMENT 
 This Agreement, made and entered into this 18th day of June, 1996, (the Effective Date) by and
between BRANDEIS UNIVERSITY, a not-for-profit corporation duly organized and existing under the laws of the Commonwealth of Massachusetts and having its principal office at 415 South Street, Waltham, Massachusetts 02254 U.S.A. (hereinafter referred
to as “BRANDEIS”), and GFA Brands, Inc., its AFFILIATE companies, and its successors or assigns, collectively referred to as GFA BRANDS, a corporation duly organized and existing under the laws of the State of Ohio and having its principal
office at 211 Knickerbocker Road, Cresskill, NJ 07626 (hereinafter referred to as “LICENSEE”). 
 WITNESSETH 
 WHEREAS, BRANDEIS is the owner of certain Technology relating to the use of a balanced proportion of saturated and polyunsaturated fatty acids from one or more vegetable
oil sources for incorporation into any and all food products to increase HDL and the HDL/LDL cholesterol ratio, and accompanying know-how (hereinafter THE TECHNOLOGY), and has the right to grant licenses thereunder; 
 WHEREAS, BRANDEIS desires to have THE TECHNOLOGY utilized in the public interest and is willing to grant a sole and exclusive license thereunder; 
 WHEREAS, LICENSEE acknowledges the valuable benefits which may accrue to LICENSEE by virtue of the grant to LICENSEE of commercialization rights hereunder, and agrees
that the royalty rates and other agreed to consideration reflect such benefits, and BRANDEIS recognizes that patent protection will enhance commercialization and hence has filed a patent application in the United States on THE TECHNOLOGY (see
attached); and 
 WHEREAS, LICENSEE desires to obtain a license hereunder upon the terms and conditions hereinafter set forth. 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties hereto agree as follows: 
 ARTICLE I - DEFINITIONS 
 For the purposes of this
Agreement, the following words and phrases shall have the following meanings: 
  

	1.1	“LICENSEE” shall mean GFA BRANDS and any AFFILIATE or SUBSIDIARY thereof. 

  

	1.2	“SUBSIDIARY” shall mean any corporation, division, company or other entity more than fifty percent (50%) of whose voting stock is owned or controlled directly or
indirectly by LICENSEE. 

  

	1.3	 “THE TECHNOLOGY” shall mean certain know-how, technical data, and information, relating to the product and its use, said product being one or more
vegetable oils providing a balance of saturated and polyunsaturated fatty acids 

  

 1 

	 	 
for incorporation into any and all food products to increase HDL and the HDL/LDL cholesterol ratio in human serum, and accompanying know-how, and the U.S.
patent application describing and claiming same, as more fully described and/or listed in Appendix A hereto and made a part hereof, whether or not it is of a confidential nature or patentable. 

  

	1.4	“PATENT RIGHTS” shall mean the United States Patent Application entitled “Increasing the HDL Level and the HDL/LDL Ratio in Human Serum With Fat Blends,” a copy
of which application is appended hereto along with a copy of the corresponding patent assignment and power of attorney documents as part of Appendix A and made a part hereof (hereinafter referred to as the “PATENT RIGHTS PATENT(S)”)
describing and claiming THE TECHNOLOGY, and any corresponding foreign and subsequent U.S. or foreign patent applications (hereafter referred to as the ‘PATENT RIGHT PATENT APPLICATION(S)”) describing and claiming THE TECHNOLOGY, and any
continuations, continuations-in-part, divisions, reissues or extensions of any of the foregoing. 

  

	1.5	“LICENSED PRODUCT(S)” shall mean any natural vegetable oil, genetically selected or engineered vegetable oil, blend of such oils, or any oil-based food without limitation,
for any and all food uses, sold in any and all marketplaces, and providing a balance of saturated and polyunsaturated fatty acids to increase HDL and the HDL/LDL cholesterol ratio in human serum, for the specific purpose of claims of HDL/LDL balance
which: 

  

	 	(a)	is covered in whole or in part by (i) a claim contained in PATENT RIGHTS PATENT APPLICATION in the country in which the LICENSED PRODUCT(S) is made, used or sold or (ii) a
valid and unexpired claim contained in a PATENT RIGHTS PATENT in the country in which the LICENSED PRODUCT(S) is made, used or sold, or 

  

	 	(b)	incorporates or is manufactured using any of THE TECHNOLOGY. 

  

	1.6	“SUBLICENSEE” shall mean any corporation or other commercial entity which is not a SUBSIDIARY or AFFILIATE of LICENSEE. 

  

	1.7	“AFFILIATE” shall mean all companies controlled by, or in common control with, LICENSEE. 

 ARTICLE II - GRANT 
  

	2.1	BRANDEIS hereby grants to LICENSEE a worldwide, sole and exclusive right and license to make, have made, use, lease and sell the LICENSED PRODUCT(S). Unless said Agreement is sooner
terminated as hereinafter provided, the term of said right and license shall be as follows: 

  

	 	(a)	In any country(s) where PATENT RIGHTS are granted, to the full end of the term of such PATENT RIGHT(S) in said country(s); 

  

	 	(b)	In any country(s) where PATENT RIGHT(S) are either not applied for, or if applied for, not granted, for a period of seventeen (17) years from the Effective Date of this
Agreement. 

  

 2 

	2.2	LICENSEE shall have the right to sublicense any of the rights, privileges and license granted hereunder, only with the prior written approval of BRANDEIS, which permission shall not
be unreasonably withheld. 

  

	2.3	LICENSEE agrees that any sublicense agreements signed by it shall contain a clause stating that the obligations of this Agreement including royalty payment obligations shall be
binding upon the SUBLICENSEE as if it were in the place of LICENSEE. 

  

	2.4	LICENSEE agrees to forward to BRANDEIS a copy of any and all fully executed sublicense agreements, and further agrees to forward to BRANDEIS annually a copy of such reports received
by LICENSEE from its SUBLICENSEES during the preceding twelve (12) month period under the sublicenses as shall be pertinent to a royalty accounting under said sublicense agreements. 

  

	2.5	LICENSEE shall not receive from SUBLICENSEES anything of value in lieu of monetary payments based upon payment obligations of any sublicense of THE TECHNOLOGY, PATENT RIGHTS, or
LICENSED PRODUCT(S) (see Paragraphs 1.3, 1.4 and 1.5) under this Agreement without the prior written approval of BRANDEIS. 

 ARTICLE III - DUE DILIGENCE 
  

	3.1	LICENSEE shall use reasonable efforts to bring the LICENSED PRODUCT(S) to market through a thorough, vigorous, and diligent program for exploitation of the rights licensed under
this Agreement. These reasonable efforts will include LICENSEE’S agreement to minimum expenditures for the purpose of bringing the LICENSED PRODUCT(S) to market. These expenditures shall include all of LICENSEE’S direct expenditures on
commercializing LICENSED PRODUCT(S) (including but not limited to support of nutritional research, product formulation research costs, and direct costs in product marketing, promotion, and advertising). These expenditures shall total at least Thirty
Thousand Five Hundred Dollars ($30,500.) during the 1996 calendar year (including $25,000. for nutritional studies and $5,500 for patent expenses), at least One Hundred Thousand Dollars ($100,000.) during the 1997 calendar year, and at least One
Hundred Thousand Dollars ($100,000.) during the 1998 calendar year. Following the end of each calendar year, and no later than sixty days following a written request by BRANDEIS, LICENSEE shall provide an accounting of these expenditures for the
preceding year to ensure satisfaction of this requirement. LICENSEE shall be deemed to have met its obligation under this paragraph if these minimum expenditures are made as scheduled, and are directed to the LICENSED PRODUCT(S), and are used for
bringing the LICENSED PRODUCT(S) to market in a manner similar to LICENSEE’S efforts for its other products. 

  

	3.2	In addition, LICENSEE shall make a first bona fide commercial sale of a LICENSED PRODUCT within twelve (12) months following the Effective Date of this Agreement unless a delay
is required due to a governmental regulatory agency, which delay shall be explained by LICENSEE in written detail to BRANDEIS. 

  

 3 

	3.3	LICENSEE’s failure to perform in accordance with Paragraphs 3.1 and 3.2 above shall be grounds for BRANDEIS to terminate this Agreement pursuant to Paragraphs 3.4, 7.1, and 7.2
hereof, which shall be BRANDEIS’s only remedies for failure by LICENSEE to perform under Paragraphs 3.1 and 3.2. 

  

	3.4	LICENSEE’s failure to meet the twelve (12) month deadline pursuant to Paragraph 3.2 is grounds for BRANDEIS to terminate this Agreement effective immediately upon serving
LICENSEE, by certified mail at the address designated in Article XIV hereof, notice of termination of the Agreement. 

  

	3.5	BRANDEIS will provide technical assistance and support as reasonably requested, e.g., telephone conversations and on-campus meetings on an ongoing basis as long as this Agreement is
in effect. Such assistance and support will be considered part of the royalty-funded responsibilities of BRANDEIS. Off campus meetings shall be compensated by reimbursement for out of pocket expenses plus a mutually agreed-upon per diem fee, except
in cases where the patent or health claims are challenged by a governmental agency, in which case only out of pocket expenses shall be reimbursed. 

  

	3.6	BRANDEIS will actively pursue issuance of all pending patent applications and will furnish LICENSEE with copies of all related patent prosecution communications, including but not
limited to correspondence from any government agencies and departments on a timely basis. 

  

	3.7	This Agreement which is limited to natural vegetable oils will automatically extend to include improvements and associated technological developments which offer an increase in HDL
and the HDL/LDL cholesterol ratio in human serum. 

  

	3.8	BRANDEIS agrees to allow LICENSEE to use its name in association with citation of research results to inform the public in a similar manner as set forth in Appendix B on packaging,
advertising and promotional materials to establish credibility for the claims for increasing HDL and the HDL/LDL cholesterol ratio in human serum. For all other proposed uses of the name of BRANDEIS and/or the inventor(s), LICENSEE must first secure
written permission from BRANDEIS and/or the inventor(s), as appropriate, according to the following procedure, which permission shall not be unreasonably withheld: LICENSEE shall provide BRANDEIS and/or the inventor(s), as appropriate, with copies
of all of the proposed material which uses the name of BRANDEIS or the inventor(s) at least fifteen (15) days prior to use to allow BRANDEIS and/or the inventor(s) to review same, and BRANDEIS and/or the inventor(s) shall provide LICENSEE with
a written response within ten (10) business days of receipt of the material, and if LICENSEE receives no response within ten (10) business days, BRANDEIS and/or the inventor(s) shall be deemed to have approved the proposed use.

 ARTICLE IV - ROYALTIES AND CONSIDERATION 
  

	4.1	For the rights, privileges and license granted hereunder, LICENSEE shall pay to BRANDEIS or in the case of patent expenses to the designated patent attorney (in the manner
hereinafter provided to the end of the term of this Agreement): 

  

 4 

 Certain portions hereof denoted with “[***]” have been omitted pursuant to a request
for confidential treatment. An unredacted copy hereof has been filed separately with the United States Securities and Exchange Commission pursuant to a request for confidential treatment. 
  

	 	(a)	Research expenses including University overhead in the amount of Twenty-Five Thousand Dollars ($25,000) which amount shall be due and payable on the Effective Date of this
Agreement, for animal nutritional studies during calendar year 1996 in the laboratory of Dr. K.C. Hayes, utilizing the LICENSED PRODUCT(S) and related oil and fat blends in controlled diets. In conjunction with this research and in support of
the LICENSED PRODUCT(S), Dr. Hayes will provide technical advice as needed and, should LICENSEE request additional animal and/or human studies, BRANDEIS will help design and conduct such studies. BRANDEIS and LICENSEE shall mutually agree on
the appropriate costs for such additional studies, with LICENSEE being solely responsible for funding such studies. 

  

	 	(b)	Royalties, for such LICENSED PRODUCT(S) used or sold by LICENSEE during the period of this Agreement, in an amount equal to: 

  

	 	(i)	— **** per pound of oil and/or fat utilized in LICENSED PRODUCT(S) containing between ***% and ***% by weight oil and/or fat, 

  

	 	 	— **** per pound of’ oil and/or fat utilized in LICENSED PRODUCT(S) containing between ***% and ***% by weight oil and/or fat, 

  

	 	 	— **** per pound of oil and/or fat utilized in LICENSED PRODUCT(S) containing between ***% and ***% by weight oil and/or fat, 

  

	 	 	— **** per pound of oil and/or fat utilized in LICENSED PRODUCT(S) containing ***% or less by weight oil and/or fat. 

  

	 	(ii)	     ****% of any and all sublicense issue fees, royalties, and any other payments received by LICENSEE in conjunction with any sublicense issued under this
Agreement 

  

	 	(c)	To the best of BRANDEIS’ knowledge, none of The Technology infringes the rights of any third party. In the event such infringements are alleged by third parties, BRANDEIS
agrees to investigate the situation fully in collaboration with LICENSEE, and the parties agree to collaborate in taking appropriate action to deal with the problem that may be exposed. If it is determined by a court, arbitrator or other authority
having jurisdiction over the issue of infringement that THE TECHNOLOGY causes the making, using, selling or offering for sale of LICENSED PRODUCT(S) to infringe the rights of a third party, or if BRANDEIS and LICENSEE agree that it is practical to
dispose of a third party’s charge of infringement by making an agreement with the third party, then any payments made to the third party shall be deducted from royalties payable to BRANDEIS, but in no case retroactively, or deductible at a rate
exceeding that payable to BRANDEIS. 

  

	4.2	All monies payable to BRANDEIS under Paragraph 4.1(b) shall be considered due and owed to BRANDEIS semi-annually payable no later than July 31 for January through June incomes
received, and payable no later than January 31 for the preceding July through December incomes received. 

  

 5 

	4.3	All payments due under Paragraph 4.1(a) that are not paid for whatever reason when due, and all payments due under Paragraphs 4.1(b) and 4.2 that are not paid for whatever reason
within 30 days of the end of a given calendar half year when due are delinquent on the next day (the 31st day after the end of that given calendar half year) and are then subject to the addition of interest at the annual rate of prime + 2%,
calculated from the date of delinquency (31 days after the end of the given calendar half year) to the date a negotiable payment check is mailed for all monies due and owed to BRANDEIS. 

  

	4.4	No multiple royalties shall be payable because the LICENSED PRODUCT(S) are or shall be covered by more than one patent application or patent licensed under this Agreement.

  

	4.5	Royalty payments shall be paid in United States dollars in Waltham, Massachusetts, or at such other place as BRANDEIS may reasonably designate within the United States. If any
currency conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by using the exchange rate prevailing at a first-class foreign exchange bank on the last business day of the calendar half
year reporting period to which such royalty payments relate. 

  

	4.6	Prior to December 31, 1997, LICENSEE shall have the right to early termination of this Agreement without penalty, upon thirty (30) days written notice to BRANDEIS provided
that it has satisfied all of its payment obligations owed under this Agreement, said obligations which shall have matured as of the termination date of this Agreement. If the Due Diligence expenditures of Paragraph 3.1 have not been met and
demonstrated by a written accounting to BRANDEIS prior to such early termination, LICENSEE shall pay to BRANDEIS with said written termination notice, a termination fee of Twenty Five Thousand Dollars ($25,000) in addition to such other payment
obligations owed under this Agreement, said obligations which shall have matured as of the termination date of this Agreement. However, such termination fee will not apply for the following occurrences which are beyond the control of LICENSEE:

  

	 	(a)	the animal research studies do not support the patent claims (see Paragraph 7.3). 

  

	 	(b)	the U.S. patent application receives a final rejection. 

  

	 	(c)	infringement claims are asserted by a third party and are not resolved pursuant to Paragraph 4.1 (c). 

  

	 	(d)	any government agency forbids use by LICENSEE of the underlying health claims regarding increasing HDL and the HDL/LDL cholesterol ratio. 

 ARTICLE V - REPORTS AND RECORDS 
  

	5.1	 LICENSEE shall keep full, true and accurate books of account containing all particulars that may be necessary for the purpose of showing the amount due and payable
to BRANDEIS as aforesaid, and the amounts spent pursuant to Paragraph 3.1 of this Agreement. Said books and the supporting data shall be kept at LICENSEE’s principal 

  

 6 

	 	 
place of business or the principal place of business of the appropriate SUBSIDIARY of LICENSEE to which this Agreement directly relates. Said books and the
supporting data shall be open at all reasonable times, for three (3) years following the end of the calendar year to which they pertain, to the inspection of the BRANDEIS Internal Audit Division and/or an independent certified public accountant
retained by BRANDEIS and/or a certified public accountant employed by BRANDEIS, for the purpose of verifying at BRANDEIS’ expense LICENSEE’s royalty statement or compliance in other respects with this Agreement. Auditing of LICENSEE books
and supporting data by a representative of BRANDEIS can occur during normal business hours upon thirty (30) days written request. 

  

	5.2	LICENSEE, within thirty (30) days after June 30 and December 31, of each year, shall deliver to BRANDEIS true and accurate reports, giving such particulars of the
business conducted by LICENSEE during the preceding six-month period under this Agreement as shall be pertinent to a royalty accounting hereunder. These reports shall include at least the following: 

  

	 	(a)	List of LICENSED PRODUCTS sold, with their weight percentage of oil and/or fat. 

  

	 	(b)	Quantity (weight) of LICENSED PRODUCT(S) sold. 

  

	 	(c)	Total fees and royalties due from all sales, uses and sublicenses. 

  

	 	(d)	Names and addresses of all SUBLICENSEES of LICENSEE. 

 ARTICLE VI - PATENT PROSECUTION AND FEES 
  

	6.1	BRANDEIS has filed a United States Patent Application as set forth in Appendix A. Brandeis may apply for any subsequent U.S. and foreign patent applications it deems necessary or
desirable, after consultation with LICENSEE. 

  

	6.2	BRANDEIS shall be responsible, other than as provided in Paragraph 6.4, for providing and maintaining all patent protection which the parties agree are necessary for supporting the
marketing effort based upon the TECHNOLOGY and health claims. LICENSEE shall contribute Five Thousand Five Hundred Dollars ($5,500.) toward this expense upon execution of this Agreement. In advance of this execution, BRANDEIS has filed the
appropriately updated U.S. patent application (a CIP filing), a Canadian patent application and a PCT foreign application. Prior to the abandonment of any patent application or lapse of any patent rights, BRANDEIS shall tender to LICENSEE an
assignment of the application or patent so as to permit LICENSEE to prosecute and maintain it at LICENSEE’s own expense for its own benefit. 

  

	6.3	If: (1) a PATENT RIGHTS PATENT describing and claiming THE TECHNOLOGY should fail to be granted in the U.S. by December 31, 1998, or (2) the PATENT RIGHTS PATENT
APPLICATION attached as Appendix A is abandoned or otherwise terminated, or (3) a patent issuing from the PATENT RIGHTS PATENT APPLICATION attached as Appendix A is allowed to lapse or is found by a court or agency of qualified jurisdiction to
be invalid or unenforceable, the aforesaid royalty rates specified in Paragraph 4.1(b)(i) shall be reduced by fifty percent (50%). 

  

 7 

	6.4	LICENSEE shall have a fifteen (15) month option period from the date of this Agreement to authorize BRANDEIS to file and prosecute patent applications through patent allowance
and issuance (or alternatively to final rejection) in individual foreign countries outside of the U.S. and Canada (herein termed DESIGNATED FOREIGN COUNTRIES) at LICENSEE’S sole expense. For any DESIGNATED FOREIGN COUNTRY, the aforesaid royalty
rates for payments to BRANDEIS pursuant to Paragraph 4.1(b)(i) shall be reduced by fifty percent (50%) until all of the expenses for the foreign patent in such a DESIGNATED FOREIGN COUNTRY are reimbursed. Notwithstanding the above, at any time
following the Effective Date of this Agreement, upon thirty (30) days written notice to BRANDEIS, LICENSEE shall have the right to cease incurring new expenses for patent prosecution and/or patent maintenance in any DESIGNATED FOREIGN COUNTRY.
If and when such a cessation should occur, BRANDEIS shall have the option, in its sole discretion and at its sole expense, to continue such patent prosecution and/or maintenance. 

 ARTICLE VII - TERMINATION 
  

	7.1	Should LICENSEE fail in its remittance to BRANDEIS, of monies due in accordance with the terms of this Agreement, BRANDEIS shall have the right to serve upon LICENSEE, by certified
mail at the address designated in Article XIV hereof, notice of termination of this Agreement effective sixty (60) days after mailing of such notice unless LICENSEE shall pay to BRANDEIS, within the sixty (60) day period, all such monies
(including fees and royalties) due and payable, with the exception of those royalties affected (herein termed AFFECTED ROYALTIES) by LICENSEE’s infringement payments pursuant to Paragraph 4.1(c) and/or LICENSEE’s foreign patent payments
pursuant to Paragraph 6.4. Any default in payment of AFFECTED ROYALTIES shall be remedied pursuant to Paragraph 7.2. Upon the expiration of the sixty (60) day period, if LICENSEE shall not have paid all such monies due and payable, the rights,
privileges and license granted hereunder shall thereupon immediately terminate in full. This Paragraph 7.1 shall always take precedence over any breach or default referred to in Paragraph 7.2. 

  

	7.2	Upon any breach or default of this Agreement by LICENSEE, other than those occurrences set out in Paragraphs 7.1 and 3.4 hereinabove, BRANDEIS shall have the right to serve upon
LICENSEE, by certified mail at the address designated in Article XIV hereof, notice of termination of this Agreement effective upon expiration of a sixty-three (63) day period. Upon the expiration of the sixty-three day period, if LICENSEE
shall not have cured such breach(es), the rights, privileges and license granted hereunder shall thereupon immediately terminate in full. Any dispute under this Paragraph shall be submitted to an arbitration mechanism acceptable to, and binding upon
both parties. 

  

 8 

	7.3	LICENSEE shall have the right to terminate this Agreement at any time during calendar years 1996 and 1997 pursuant to Paragraph 4.6, and after January 1, 1998 upon ninety
(90) days prior notice. Such notice shall be by certified mail to BRANDEIS. Thereafter, no further payments shall be due except those pursuant to Paragraphs 7.4 and 7.5. 

  

	7.4	Upon termination of this Agreement for any reason, LICENSEE and/or SUBLICENSEE thereof may sell all LICENSED PRODUCTS, and complete LICENSED PRODUCTS in the process of manufacture
at the time of such termination and sell the same, provided that LICENSEE shall pay to BRANDEIS the royalties due thereon as required by Article IV of this Agreement and shall submit the reports required by Article V hereof on such sales.

  

	7.5	Upon termination of this Agreement for any reason, nothing herein shall be construed to release either party from any obligation that matured prior to the effective date of such
termination. 

  

	7.6	Upon termination of this Agreement for any reason, all sublicense agreements entered into by LICENSEE shall remain in full force and effect with BRANDEIS being substituted in the
sublicense agreement in place of LICENSEE. 

 ARTICLE VIII - LEGAL RECOURSE 
  

	8.1	Claims, disputes or controversies arising under, out of, or in connection with this Agreement or issues concerning the validity, construction or effect of any patent licensed
hereunder shall be resolved in any court having jurisdiction thereof. 

  

	8.2	Notwithstanding the foregoing, nothing in this Article shall be construed to waive any rights or time performance of any obligations existing under this Agreement.

 ARTICLE IX - INFRINGEMENT 
  

	9.1	LICENSEE and BRANDEIS shall promptly inform each other in writing of any alleged infringement of which it shall have notice committed by a third party regarding any patents within
the PATENT RIGHTS and shall provide such other with any available evidence of such infringement. 

  

	9.2	During the term of this Agreement, LICENSEE shall have the rights, but shall not be obligated, to prosecute at its own expense any infringements of the PATENT RIGHTS and, in
furtherance of such right, LICENSEE hereby agrees that BRANDEIS may join LICENSEE as a party plaintiff in any infringement suit, without expense to LICENSEE. The total cost of any infringement action commenced or defended solely by LICENSEE shall be
borne by LICENSEE and LICENSEE shall keep any recovery or damages for past infringement derived therefrom in keeping with Paragraph 9.4. 

 If BRANDEIS and LICENSEE mutually agree to join together in the prosecution of any such infringement, the expenses for such prosecution shall be equally divided between 

  

 9 

 
BRANDEIS and LICENSEE. Any recovery or damages for past infringement derived therefrom shall be applied first in satisfaction of any unreimbursed expenses
and reasonable legal fees of both parties, and the balance remaining from such recovery shall be divided equally between LICENSEE and BRANDEIS. 
  

	9.3	If within ninety (90) days after having been notified of any alleged infringement, LICENSEE shall have been unsuccessful in persuading the alleged infringer to desist and shall
not have brought and shall not be prosecuting an infringement action, or if LICENSEE shall notify BRANDEIS at any time prior thereto of its intention not to bring suit against any alleged infringer, then, BRANDEIS shall have the right, but shall not
be obligated, to prosecute at its own expense any infringement of the PATENT RIGHTS, and LICENSEE may, for such purposes, join BRANDEIS as a party plaintiff, without expense to BRANDEIS. No settlement, consent judgment or other voluntary final
disposition of an infringement suit may be entered into without the consent of both BRANDEIS and LICENSEE where both are parties joined in the suit, which consent shall not unreasonably be withheld. 

  

	9.4	In the event that LICENSEE shall undertake the enforcement and/or defense of the PATENT RIGHTS by litigation LICENSEE may withhold up to fifty percent (50%) of the royalties
otherwise thereafter due BRANDEIS hereunder and apply the same toward reimbursement of its expenses, including reasonable attorneys’ fees, court reporters, transcripts, expert witnesses, and exhibits in connection therewith. Any recovery of
damages by LICENSEE for any such suit shall be applied first in satisfaction of any unreimbursed expenses and legal fees of LICENSEE relating to the suit, and next toward reimbursement of BRANDEIS for any royalties past due or withheld and applied
pursuant to this Article IX. The balance remaining from any such recovery shall be divided equally between LICENSEE and to BRANDEIS. 

  

	9.5	In the event that a declaratory judgment action alleging invalidity or infringement of any of the PATENT RIGHTS shall be brought against LICENSEE, BRANDEIS, at its option, shall
have the right, within thirty (30) days after commencement of such action has been noticed to BRANDEIS, to intervene and take over the sole defense of the action at its own expense. Any recovery of damages by BRANDEIS shall be applied first in
satisfaction of any unreimbursed expenses of both BRANDEIS and LICENSEE. If BRANDEIS elects not to intervene, LICENSEE may assume the defense and may escrow annually fifty (50%) percent of royalties otherwise due BRANDEIS and apportion any
damages in the same proportions and to the same extent as set forth in Paragraph 9.4 hereof. Any obligation of BRANDEIS to reimburse LICENSEE shall cease upon termination of this Agreement. 

  

	9.6	 In any infringement suit as either party may institute to enforce the PATENT RIGHTS or in any defense of the PATENT RIGHTS pursuant to this Agreement, the other
party hereto shall, at the request and expense of the party initiating such suit, cooperate in all 

  

 10 

	 	 
respects, including being named as a party to the suit in order to facilitate compliance with legal requirements for joinder of parties and, to the extent
possible, have its employees testify when requested and make available relevant records, papers, information, samples, specimens, and the like. 

  

	9.7	LICENSEE, during the period of this Agreement, shall have the right with the concurrent approval of BRANDEIS in accordance with the terms and conditions of this Agreement to
sublicense any alleged infringer under the PATENT RIGHTS relating to past and future infringements. 

 ARTICLE X - PRODUCT
LIABILITY 
 Except for matters arising from BRANDEIS’s own acts or omissions, LICENSEE shall at all times during the term of this Agreement and
thereafter, indemnify, defend and hold BRANDEIS, its trustees, officers, employees and AFFILIATES, harmless against all claims and expenses, including legal expenses and reasonable attorneys’ fees, arising out of the death of or injury to any
person or persons or out of any damage to property and against any other claim, proceeding, demand, expense and liability of any kind whatsoever resulting from the production, manufacture, sales, use, lease, consumption or advertisement of the
LICENSED PRODUCT(S) by LICENSEE or SUBLICENSEE if any. 
 ARTICLE XI - ASSIGNMENT 
 LICENSEE may not assign or otherwise transfer this Agreement and the license granted hereby and the rights acquired hereunder without the prior written approval of
BRANDEIS, which approval shall not be unreasonably withheld, unless such assignment or transfer shall be accompanied by a sale or other transfer of LICENSEE’s business, or by a sale or other transfer of all of the assets of LICENSEE’S
business unit relating to the LICENSED PRODUCT(S), including product formulations, brand names, receivables and inventory. For any other assignment or transfer, LICENSEE shall give BRANDEIS thirty (30) days prior notice of such assignment and
transfer, and if BRANDEIS raises no objection to such assignment or transfer in writing within said thirty (30) days, then BRANDEIS shall be deemed to have approved such assignment or transfer; however, BRANDEIS shall not be deemed to have
approved such assignment and transfer unless such assignee or transferee shall have first agreed in a written statement to LICENSEE and BRANDEIS to be bound by the terms and conditions of this Agreement. Upon such agreement in writing by such
assignee or transferee, and such assignment or transfer, the term LICENSEE as used herein shall include such assignee or transferee. If LICENSEE assigns or otherwise transfers this Agreement, and the transferee shall not have agreed in writing to be
bound by the terms and conditions of this Agreement, then this Agreement shall be terminable at will at the option of BRANDEIS. 
  

 11 

 BRANDEIS’s right to assign or otherwise transfer this Agreement is subject to the same terms and
conditions as those imposed on LICENSEE 
 ARTICLE XII - OWNERSHIP OF INTELLECTUAL PROPERTY 
  

	12.1	BRANDEIS shall retain right, title and ownership interest in all of the intellectual property described in this Agreement subject only to the license granted herein to LICENSEE.

  

	12.2	Trade-secret formulations developed or utilized by LICENSEE shall remain the property of LICENSEE, as well as all trademarks and marketing plans used to sell and distribute products
utilizing the TECHNOLOGY. 

  

	12.3	Any patented inventions improving upon the PATENT RIGHTS’s increase of HDL and the HDL/LDL cholesterol ratio in human serum which are developed by LICENSEE, its agents or its
SUBLICENSEES shall be the property of BRANDEIS provided, however, that LICENSEE may utilize and sublicense them without changing the terms of this AGREEMENT. 

 ARTICLE XIII - EXPORT CONTROLS 
 It is understood that BRANDEIS is subject to United States laws and regulation
controlling the export of technical data, computer software, laboratory prototypes and other commodities (including the Arms Export Control Act, as amended, and the Export Administration Act of 1979), and that its obligations hereunder are
contingent on compliance with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the cognizant agency of the United States Government and/or written assurances by
LICENSEE that LICENSEE shall not export data or commodities to certain foreign countries without prior approval of such agency. BRANDEIS neither represents that a license shall not be required nor that, if required, it shall be issued. 

ARTICLE XIV - PAYMENTS, NOTICES AND OTHER COMMUNICATIONS 
 Notices or other communications pursuant to compliance with this Agreement shall be deemed sufficiently made or given on the date of mailing if sent to such party by certified first class mail, postage prepaid, addressed to it at its
address below (or at an address as either party shall designate by written notice given to the other party); 
  

			
	In the case of BRANDEIS:	  	Director, Grant, Contract and Patent Administration
		  	Brandeis University
		  	Waltham, MA 02254-9110
		
	In the case of LICENSEE:	  	GFA Brands, Inc.
		  	211 Knickerbocker Road
		  	Cresskill, NJ 07626

  

 12 

 ARTICLE XV - MISCELLANEOUS PROVISIONS 
  

	15.1	This Agreement shall be construed, governed, interpreted and applied in accordance with the laws of the Commonwealth of Massachusetts, U.S.A., except that questions affecting the
construction and effect of any patent shall be determined by the law of the country in which the patent was granted. 

  

	15.2	The parties hereto acknowledge that this Agreement sets forth the entire Agreement and understanding of the parties hereto as to the subject matter hereof, and shall not be subject
to any change or modification except by the execution of a written instrument subscribed to by the parties hereto. 

  

	15.3	The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any controlling body
of law, such invalidity or unenforceability shall not in any way affect the validity or enforceability or the remaining provisions hereof. 

  

	15.4	LICENSEE, agrees to mark the LICENSED PRODUCTS sold in the United States with all applicable United States patent numbers as appropriate. All LICENSED PRODUCTS shipped to or sold in
other countries shall be marked in such manner as to conform with the patent laws and practice of the country of manufacture or sale. 

  

	15.5	The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or
excuse a similar subsequent failure to perform any such term or condition by the other party. 

 IN WITNESS WHEREOF, the parties hereto have
hereunto set their hands and seals and duly executed this License Agreement the day and year first set forth below. 
  

									
	BRANDEIS UNIVERSITY	 		 	GFA BRANDS, INC.
					
	By:	 	/s/ Joel M. Cohen	 		 	By:	 	/s/ Robert M. Harris
	Title:	 	Assistant Provost for Research	 		 	Title:	 	CEO
	Date:	 	6/19/96	 		 	Date:	 	June 18, 1996

  

 13 

 APPENDIX    B        Page 1 of 5 
 

 
  

 14 

 APPENDIX    B        Page 2 of 5 
 

 
  

 15 

 APPENDIX    B        Page 3 of 5 
 NEW FROM BRANDEIS UNIV. RESEARCH 
 SMART BEAT®

 SMART OILTM 
 PATENT PENDING 
 SALAD & COOKING OIL BLEND 
 NUTRITION SUPPLEMENT 
 NEW PLAN TO IMPROVE 
 HDL / LDL CHOLESTEROL* 
 SEE BACK PANEL FOR NUTRITION INFORMATION 
 NET WT. 16 FL OZS 
 BACK PANEL 
  

	•	 	 PLAN TO IMPROVE 

 HDL / LDL CHOLESTEROL

  

	*	Exercize Regularly 

  

	*	Don’t Smoke 

  

	*	Reduce Fat to Less 

	 	Than 30% of Calories 

  

	*	See Doctor Regularly 

  

	*	Use Smart Oil* To 

	 	Replace Other Fats 

	 	Based on 

	 	Brandeis University Research 

  

	 	(Eventual Name of Oil and other Foods) 

  

 16 

 APPENDIX    B        Page 4 of 5 
 Sample Live Radio Spot—“NEW FROM BRANDEIS UNIVERSITY RESEARCH” 
 This is _________ to announce a totally new idea in healthy foods from Brandeis University Research. It’s called Smart Oil (Code Name) and its in the bottled oil section, the margarine department and the cheese
case of your supermarket. This remarkable new oil is actually a perfect balance of polyunsaturates, monounsaturates and saturates to improve the critical ratio of HDL and LDL cholesterol in your cardio vascular system. Chances are you know that HDL
is referred to as good cholesterol and a diet with Smart Oil, used as a food supplement on your salads, on your vegetables, in your cooking and as a spread for sandwiches and toast, may actually increase your HDL good cholesterol and improve the
HDL/LDL cholesterol ratio, that important blood lipid ratio. Nutritionists and health professionals talk about the desirability of keeping TOTAL cholesterol below the “magic 200 level”. It is still important to keep total cholesterol low
but the ratio of HDL to LDL cholesterol is most important to reduce the risk of heart disease and stroke. Obviously, there are other critical factors such as smoking, controlling blood pressure and proper exercise. But now Brandeis University
research, gives you a new tool in the battle against heart disease and stroke. I urge you to see your doctor and ask him to fill you in about new Smart Oil–the food supplement to increase HDL Cholesterol and improve the HDL/LDL ratio. Of course
no food is worth much unless it tastes good. Smart Oil has a light delicate flavor your whole family will enjoy on salads and in cooking. 
  

 17 

 APPENDIX    B        Page 5 of 5 
 New From Brandeis University Research 
 SMART OILTM FOR SALADS AND COOKING AND SMART SPREADTM INSTEAD OF BUTTER AND MARGARINE, TO HELP
INCREASE YOUR HDL (GOOD CHOLESTROL) AND IMPROVE YOUR HDL/LDL RATIO. THAT’S IMPORTANT 
 BRANDEIS CREATED SMART OILTM — A PERFECT BALANCE OF POLYUNSATURATES, MONOUNSATURATES AND SATURATES TO
REPLACE OTHER FATS IN YOUR DIET, WITH THE GOAL OF BOOSTING HDL—THE GOOD KIND OF CHOLESTEROL WHICH REMOVES THE LDL BAD CHOLESTEROL FROM YOUR BODY. IT’S NOT JUST TOTAL CHOLESTEROL, IT’S THE HDL/LDL RATIO THAT’S CRITICALLY IMPORTANT
! 
 Scientists at Brandeis University have found a way to increase HDL
cholesterol with the right balance of fats in your diet. It is a fact that polyunsaturates can help lower your total cholesterol but you want to raise, not lower, HDL (good cholesterol). By combining polyusaturates (and monounsaturates)
together with the right kind of saturates, Brandeis scientists found that this Smart Oil TM improve the HDL/LDL
cholesterol ratio. 
 MAKE SMART BEAT’S SMART OILTM & SMART SPREADTM

 AN IMPORTANT PART OF YOUR HEALTHY DIET 
  

 18 

 Certain portions hereof denoted with “[***]” have been omitted pursuant to a request
for confidential treatment. An unredacted copy hereof has been filed separately with the United States Securities and Exchange Commission pursuant to a request for confidential treatment. 
 ADDENDUM TO LICENSE AGREEMENT 
 This ADDENDUM NUMBER 1
(hereinafter abbreviated “Addendum”) to the LICENSE AGREEMENT dated June 18, 1996 by and between BRANDEIS UNIVERSITY organized and existing under the laws of the Commonwealth of Massachusetts and located in Waltham, MA, and GFA
BRANDS, INC. organized and existing under the laws of Ohio and located in Cresskill, NJ. 
 The purpose of this Addendum is to extend the
scope of the License Agreement to include the manufacture, use, lease and sale of bulk oils and blended shortening compositions containing palm oil and/or any fractionated product of palm oil or palm kernel oil, combined with corn oil (the
“Licensed Product(s)”). A more detailed description of the new technology being added to the License Agreement by means of this Addendum is provided in the accompanying patent application entitled “Blends of Palm Fat and Corn Oil
Provide Oxidation-Resistant Shortenings for Baking and Frying” attached as Appendix A. 
 All of the terms of the License Agreement
shall apply to this addendum and to the manufacture, use, lease, and sale of the shortenings herein described with the following exceptions: 
 1. The
definitions in Paragraphs 1.3, 1.4, and 1.5 are amended to include the shortening described herein and the patent application attached as Appendix A. 
 2.
The royalty schedule under, and only under Paragraph 4.1(b)(i) of the License Agreement is reduced by ***% for the Licensed Product(s) described herein, but only in the commercial field, and only for such Licensed Product(s) sold directly by GFA
BRANDS, INC. This provision does not apply to products sold by sublicensees pursuant to Paragraph 4.1(b)(ii). By the term “commercial field” is meant any food service use, e.g., frying shortening for restaurants, or any industrial
manufacturing use, e.g., shortening for commercial bakers. The royalty schedule for retail sale for consumer use is not changed. 
 Notwithstanding the above, if the average net sales price per pound of the Licensed Product(s) increases or decreases from one year to the next during the lifetime of the License Agreement, then the modified royalty schedule herein,
will be adjusted proportionately upward or downward for that year, to maintain an approximately constant percentage return on net sales of Licensed Product(s). Average net sales price for the Licensed Product(s) sold in a given calendar year under
this Addendum, shall be calculated at calendar year end, by dividing the total net sales for these Licensed Product(s), by the total number of pounds of Licensed Product(s) sold that year. For the purposes of this Addendum, net sales are defined as
gross sales less cash, trade, and promotional allowances, and freight where it applies. These deductions do not include other sales and marketing expenses. 
 3. Patent filing, prosecution, and maintenance expenses under Paragraph 6.2 of the License Agreement for the patent application (attached as Appendix A) shall be the responsibility of GFA BRANDS, INC. rather than BRANDEIS UNIVERSITY.

  

									
	for BRANDEIS UNIVERSITY	 		 	for GFA BRANDS, INC.
					
	Name:	 	/s/ Joel M. Cohen	 		 	Name:	 	/s/ Robert M. Harris
		 	JOEL M. COHEN	 		 		 	
	Title:	 	Assistant Provost for Research	 		 	Title:	 	CEO
	Date:	 	12/4/96	 		 	Date:	 	12/11/96

  

 19 

 Certain portions hereof denoted with “[***]” have been omitted pursuant to a request
for confidential treatment. An unredacted copy hereof has been filed separately with the United States Securities and Exchange Commission pursuant to a request for confidential treatment. 
 ADDENDUM TO LICENSE AGREEMENT 
 This ADDENDUM NUMBER 1
(hereinafter abbreviated “Addendum”) to the LICENSE AGREEMENT dated June 18, 1996 by and between BRANDEIS UNIVERSITY organized and existing under the laws of the Commonwealth of Massachusetts and located in Waltham, MA, and GFA
BRANDS, INC. organized and existing under the laws of Ohio and located in Cresskill, NJ. 
 The purpose of this Addendum is to extend the
scope of the License Agreement to include the manufacture, use, lease and sale of bulk oils and blended shortening compositions containing palm oil and/or any fractionated product of palm oil or palm kernel oil, combined with corn oil (the
“Licensed Product(s)”). A more detailed description of the new technology being added to the License Agreement by means of this Addendum is provided in the accompanying patent application entitled “Blends of Palm Fat and Corn Oil
Provide Oxidation-Resistant Shortenings for Baking and Frying” attached as Appendix A. 
 All of the terms of the License Agreement
shall apply to this addendum and to the manufacture, use, lease, and sale of the shortenings herein described with the following exceptions: 
 1. The
definitions in Paragraphs 1.3, 1.4, and 1.5 are amended to include the shortening described herein and the patent application attached as Appendix A. 
 2.
The royalty schedule under, and only under Paragraph 4.1(b)(i) of the License Agreement is reduced by ***% for the Licensed Product(s) described herein, but only in the commercial field, and only for such Licensed Product(s) sold directly by GFA
BRANDS, INC. This provision does not apply to products sold by sublicensees pursuant to Paragraph 4.1(b)(ii). By the term “commercial field” is meant any food service use, e.g., frying shortening for restaurants, or any industrial
manufacturing use, e.g., shortening for commercial bakers. The royalty schedule for retail sale for consumer use is not changed. 
 Notwithstanding the above, if the average net sales price per pound of the Licensed Product(s) increases or decreases from one year to the next during the lifetime of the License Agreement, then the modified royalty schedule herein,
will be adjusted proportionately upward or downward for that year, to maintain an approximately constant percentage return on net sales of Licensed Product(s). Average net sales price for the Licensed Product(s) sold in a given calendar year under
this Addendum, shall be calculated at calendar year end, by dividing the total net sales for these Licensed Product(s), by the total number of pounds of Licensed Product(s) sold that year. For the purposes of this Addendum, net sales are defined as
gross sales less cash, trade, and promotional allowances, and freight where it applies. These deductions do not include other sales and marketing expenses. 
 3. Patent filing, prosecution, and maintenance expenses under Paragraph 6.2 of the License Agreement for the patent application (attached as Appendix A) shall be the responsibility of GFA BRANDS, INC. rather than BRANDEIS UNIVERSITY.

  

									
	for BRANDEIS UNIVERSITY	 		 	for GFA BRANDS, INC.
					
	Name:	 	/s/ Joel M. Cohen	 		 	Name:	 	/s/ Robert M. Harris
		 	JOEL M. COHEN	 		 		 	
	Title:	 	Assistant Provost for Research	 		 	Date:	 	12/11/96
	Date:	 	12/4/96	 		 	Title:	 	CEO

  

 20 

 Second Addendum To License Agreement 
 1. This is a Second Addendum to the License Agreement dated June 18, 1996 between Brandeis University (“Brandeis”) and GFA Brands, Inc.
(“GFA”) (the “License Agreement”), that was previously amended in an Addendum signed by Brandeis on December 4, 1996 and by GFA on December 11, 1996 (the “First Addendum”). 
 2. The purpose of this Second Addendum to clarify and modify the handling of certain legal and related expenses, and to adjust Brandeis’ share of
royalties under a particular sublicense contemplated by GFA. 
 3. This Second Addendum is effective nunc pro tunc as of January 1, 2006
(the “Effective Date”). The terms of this Second Amendment shall apply to expenses incurred from and after the Effective Date. Any disputes regarding the calculation or allocation of expenses incurred prior to the Effective Date are hereby
waived and released by both parties. 
 4. Paragraph 6.2 of the License Agreement and paragraph 3 of the First Addendum are hereby modified
to make clear that GFA will pay all U.S. and Canadian patent application and maintenance expenses. 
 5. Paragraph 6.4 of the License
Agreement shall be modified to make clear that patent application and maintenance expenses in countries other than in the U.S. and Canada will be evenly shared between Brandeis and GFA. All such expenses will be paid in the first instance by GFA;
GFA will then charge Brandeis’ share against royalties. 
 6. Paragraphs 9.2, 9.3 and 9.4 of the License Agreement shall be modified to
make clear that expenses associated with a prosecution of a patent infringement or litigation shall hereafter be deemed “Enforcement Expenses.” As used herein “Enforcement Expenses” shall include all expenses incurred by GFA in
dealing with use, or potential use, of the patented 
  

 21 

 Certain portions hereof denoted with “[***]” have been omitted pursuant to a request
for confidential treatment. An unredacted copy hereof has been filed separately with the United States Securities and Exchange Commission pursuant to a request for confidential treatment. 
 technology by third parties or in dealing with assertions against the validity, enforceability, or scope of the patents. By way of example (and not limitation)
Enforcement Expenses shall include: (a) expenses incurred after the filing of a suit involving the patents; (b) the work leading up to bringing a lawsuit involving the patents; (c) expenses involved in re-examinations started by third
parties; (d) expenses involved in negotiations that are entered into in an attempt to reach a sublicense agreement or other settlement arrangement whether or not a lawsuit is involved. GFA will direct counsel handling such matters. 

7. Paragraphs 9.2 and 9.4 of the License Agreement shall be modified to make clear that GFA will pay all Enforcement Expenses in the first instance
and that GFA will then have the right to charge up to ***% of those payments against Brandeis’ royalties. 
 8. Paragraphs 9.2 and 9.4
of the Agreement shall be modified to provide that, in the event of any recovery in a lawsuit or as a result of the expenditure of Enforcement Expenses, such recovery shall first be applied to reimburse each party for Enforcement Expenses to the
extent paid by the parties. If after such reimbursement any recovery remains, the balance shall be paid such that GFA would get ***% and Brandeis ***% of the remainder. 
 9. The total charges against Brandeis’ royalties pursuant to paragraphs 5 and 7 hereof shall not exceed ***% of the royalties earned in any accounting period with the remainder, if any, being carried forward to
be charged in subsequent accounting periods, subject to the proviso that the total charges against Brandeis’ royalties in any given accounting period (including charges for that period pursuant to paragraph 5 and/or 7) or any carry forward do
not exceed ***% of the royalties earned in that accounting period. 
 10. GFA is considering a license arrangement with Ventura Foods, LLC
that would involve the food service industry and would require ongoing support efforts by GFA involving 
  

 22 

 Certain portions hereof denoted with “[***]” have been omitted pursuant to a request
for confidential treatment. An unredacted copy hereof has been filed separately with the United States Securities and Exchange Commission pursuant to a request for confidential treatment. 
 substantial time commitments by GFA personnel. The parties agree that Brandeis’ share of fees, royalties and other payments under Paragraph 4.1(b)(ii) the License
Agreement shall be reduced to ***% for this sublicense to Ventura and similar sublicenses (active vs. passive) which require GFA to provide significant support services and time commitments. Brandeis share of passive sublicense income (such as
Kraft’s license) will continue at ***% of royalty income. Brandeis’ share shall also remain at ***% for existing sublicenses. 
 11. Except as expressly modified in this Second Addendum, the License Agreement and First Addendum shall continue in full force and effect. 
 12. In order to clarify without changing its intended meaning, Article XI - Assignment is rewritten to read as follows: 
 ARTICLE XI — ASSIGNMENT 
 LICENSEE may assign or otherwise transfer this Agreement and the
license granted hereby and the rights acquired hereunder without the prior written approval of BRANDEIS if such assignment or transfer shall be accompanied by a sale or other transfer of LICENSEE’s business, or by a sale or other transfer of
all of the assets of LICENSEE’S business unit relating to the LICENSED PRODUCT(S), including product formulations, brand names, receivables and inventory. Any other assignment or transfer shall require prior written approval of BRANDEIS, which
approval shall not be unreasonably withheld. LICENSEE shall give BRANDEIS thirty (30) days prior notice of such assignment and transfer requiring BRANDEIS’ approval, and if BRANDEIS raises no objection to such assignment or transfer in
writing within said thirty (30) days, then BRANDEIS shall be deemed to have approved such assignment or transfer; however, BRANDEIS shall not be deemed to have approved such assignment and transfer unless such assignee or transferee shall have
first agreed in a written statement to LICENSEE and BRANDEIS to be bound by the terms and conditions of this Agreement. Upon such agreement in writing by such assignee or transferee, and such assignment or transfer, the term LICENSEE as used herein
shall include such assignee or transferee. If LICENSEE assigns or otherwise transfers this Agreement, and the transferee shall not have agreed in writing to be bound by the terms and conditions of this Agreement, then this Agreement shall be
terminable at will at the option of BRANDEIS. 
 BRANDEIS’s right to assign or otherwise transfer this Agreement is
subject to the same terms and conditions as those imposed on LICENSEE. 
  

 23 

									
	for BRANDEIS UNIVERSITY	 		 	for GFA BRANDS, INC.
					
	By:	 	/s/ Marty Wyngaarden Krauss	 		 	By:	 	/s/ Robert M. Harris
	Title:	 	Provost	 		 	Title:	 	CEO
	Date:	 	April 18, 2006	 		 	Date:	 	April 25, 2006

  

 24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}]]